Forget bluebird bio, Amgen Is a Better Biotech Stock [The Motley Fool]
Amgen Inc. (AMGN)
Last amgen inc. earnings: 4/30 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.amgen.com
Company Research
Source: The Motley Fool
After avoiding a pitfall many of its competitors are heading for, America's largest biotechnology company looks like a much better option. In recent years, bluebird bio ( NASDAQ:BLUE ) has excited the medical community with terrific results for experimental therapies. Deep-pocketed biotechs and everyday investors have funneled billions into Bluebird and similar start-ups to help them develop complex treatments, and the competition is heating up fast. While investors become increasingly worried about Bluebird's pipeline, Amgen Inc. ( NASDAQ:AMGN ) has taken a much simpler approach that could pay off down the road. Here's why shares of the country's largest biotech probably have a better chance to outperform bluebird bio and its peers. Image source: Getty Images. Too much of a great thing In 2015, Amgen gave Kite Pharma $60 million upfront to discover new chimeric antigen receptor T-cell (CAR-T) therapies, which are actually a patient's own immune cells
Show less
Read more
Impact Snapshot
Event Time:
AMGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AMGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AMGN alerts
High impacting Amgen Inc. news events
Weekly update
A roundup of the hottest topics
AMGN
News
- Amgen's Q1 Earnings: Solid All Court Progress, Major Weight Loss Catalyst Pending [Seeking Alpha]Seeking Alpha
- Amgen Inc. (NASDAQ: AMGN) had its price target raised by analysts at UBS Group AG from $284.00 to $307.00. They now have a "neutral" rating on the stock.MarketBeat
- Amgen Inc. (NASDAQ: AMGN) had its price target raised by analysts at Morgan Stanley from $271.00 to $310.00. They now have an "equal weight" rating on the stock.MarketBeat
- Amgen Inc. (NASDAQ: AMGN) had its price target lowered by analysts at Royal Bank of Canada from $332.00 to $328.00. They now have an "outperform" rating on the stock.MarketBeat
- Amgen (AMGN) Q1 Earnings Top, Stock Up on Obesity Drug Update [Yahoo! Finance]Yahoo! Finance
AMGN
Earnings
- 5/2/24 - Beat
AMGN
Sec Filings
- 5/3/24 - Form 4
- 5/3/24 - Form 4
- 5/3/24 - Form 4
- AMGN's page on the SEC website